Economic And Quality-Of-Life Burden Of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Spain: The Ibis-C Study

  • Mearin F
  • Cortes X
  • Mackinnon J
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Objectives: The IBIS-C study assessed the burden of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, and UK). Here we present the diagnosis and management results for the Spanish cohort. Methods: Observational, retrospective- prospective (6 months each) study in patients diagnosed with moderate-tosevere IBS-C in the last five years (Rome-III criteria). Moderate-to-severe IBS-C was defined as an IBS-Symptom Severity Score (IBS-SSS) ≥ 175. Results: 112 patients were included (58% severe, mean age [±SD] 46.8 ± 13.7 years, 86% female). Mean time since diagnosis: 2.3 ± 2.7 years; mean symptom duration: 9.6 ± 9.9 years. Diagnostic procedures were highly variable; the most common were blood tests (71%), colonoscopy (56%) and abdominal ultrasound (54%). At inclusion the most prevalent symptoms were constipation (84%), abdominal pain (80%), abdominal distention (80%) and bloating (59%). Main ongoing comorbidities were dyspepsia (41%), anxiety (38%), depression (21%), headache (25%), or insomnia (25%). 58% of patients had an average of 4.1 ± 2.5 diagnostic tests during follow-up. 85% of patients took pharmacological medication (80% took some pharmacological medication for their IBS-C). The most common prescription drugs were plantago ovata (35%), otilonium bromide (22%), macrogol plus electrolites (13%) and cinitapride tartrate (10%). Likewise, common drug combinations were laxative monotherapy (21%), laxatives and antispasmodics (14%), and antispasmodic monotherapy (5%). In addition, 30% of patients received complementary therapies. Overall, marginal improvement was noted in symptom severity (IBS-SSS total score) between baseline (315±83) and the 6-month visit (234±98). Conclusions: Moderate-to-severe IBS-C symptoms often remain undiagnosed for many years. With frequent visits to health care professionals IBS-C continues to be a burden despite the availability of therapeutic interventions. Finally, current health care resource utilization is high even though there is a high degree of prescription medication use.




Mearin, F., Cortes, X., Mackinnon, J., Bertsch, J., Fortea, J., & Tack, J. (2014). Economic And Quality-Of-Life Burden Of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Spain: The Ibis-C Study. Value in Health, 17(7), A365.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free